SK Capital to acquire Swixx Biopharma at €1.5bn-plus valuation
US-based private investment firm SK Capital is to acquire a majority stake in Swixx Biopharma from HBM Healthcare Investments AG and other investors including PE firm Mérieux Equity Partners in a deal that values the pharmaceutical services group at over €1.5bn.